Connecting to SEC EDGAR… PricingSign in
← All filings
PULSE BIOSCIENCES, INC.PLSE · Nov 6, 8:40 AM ET

Pulse Biosciences reports 86% of evaluated thyroid nodule patients met six-month endpoint

Pulse Biosciences announced interim six-month results from its PRECISE-BTN study of 43 patients treated for symptomatic benign thyroid nodules, with 86% reaching at least 50% nodule volume reduction.

AI-generated summary, checked against the filing. Can contain errors: read the original filing ↗. Not investment advice.